

THE IMMUNODOMINANT STAPHYLOCOCCAL ANTIGEN A

an Attractive Target for Precision Diagnosis of Staphylococcal Infections

Taher Alawneh^{a,b}, Esmeralda Diephout^a, Joyce Vrijzen^a, Marjan Wouthuyzen-Bakker^b, Sjouke Piersma^b, Girbe Buist^b, Paul C. Jutte^a, Jan Maarten van Dijk^{b*}

^a University of Groningen, University Medical Center Groningen, Department of Orthopedics, Groningen, the Netherlands

^b University of Groningen, University Medical Center Groningen, Department of Medical Microbiology and Infection Prevention, Groningen, the Netherlands





Figure (1): 3D structural representation of the Immunodominant Staphylococcal Antigen A (IsaA). The protein folding conformation was predicted utilizing the AlphaFold artificial intelligence system. <https://alphafold.ebi.ac.uk/entry/AF-A71Y64-F1>


BACKGROUND

The clinical burden of periprosthetic joint infections (PJIs) remains profound. With *Staphylococcus aureus* being the most common causative microorganism, new and fast methods for bacteria-targeted detection and diagnosis of PJIs caused by this major pathogen are needed.



INTRODUCTION

- **IsaA** is a conserved surface protein of *Staphylococcus aureus*.
- The antigen offers **potential for developing the rapid diagnostics and targeted therapies** needed to manage periprosthetic joint infections (PJIs).
- The primary aim is to **showcase current evidence on IsaA as a diagnostic and therapeutic target for PJIs**.
- A secondary aim is to **discuss the present gaps between preclinical research and potential clinical use in orthopedic practice**.




Conserved Antigen



Easy Access



Specific to *S. aureus*




Precise Diagnosis




IsaA is targeted by




UK-66P



hUK-66



1D9 + IRDye800 CW



1D9 + IRDye700 DX




RESEARCH METHDODOLOGY



A comprehensive literature search was conducted utilizing the PubMed/MEDLINE databases



70 Identified articles focusing on IsaA's characteristics and potential clinical applications



Specific focus was placed on IsaA-directed monoclonal antibodies, namely 1D9, UK-66P, and hUK-66.



RESULT AND DISCUSSION

1. Early Models & Humanization (UK-66P & hUK-66)

- **UK-66P (Murine IgG1):** Enhanced survival rates of mice challenged with *S. aureus* in murine infection models.
- **hUK-66 (Humanized):** Successfully increased phagocytosis of the bacterium, demonstrating improved host immune response.

2. Passive Immunotherapy (1D9)

1D9 (Fully Human IgG1): Proven feasible as a standalone passive immunotherapy agent against staphylococcal infections.

3. Advanced Conjugates (1D9 + Fluorophores)

- **Diagnostic (1D9 + IRDye800CW):** Successfully visualized *S. aureus* in human post-mortem and murine infection models using near-infrared tracking.
- **Theranostic (1D9 + IRDye700DX):** A dual-action photo-activatable conjugate targeting IsaA. It enables real-time, optical imaging in vivo and, when activated with red light, produces bactericidal reactive oxygen species (ROS) to eradicate the infection.




CONCLUSION

IsaA has proven to be a target in preclinical *S. aureus* models, but the transition to clinical practice requires validation in human samples. Bridging this gap is essential for developing precision diagnostics and targeted therapies capable of overcoming the challenges of biofilm-mediated PJIs.



REFEFENCES

- Romero Pastrana F, et al. Virulence. 2018.
- Lorenz U, et al. Antimicrob Agents Chemother. 2011.
- Oesterreich B, et al. Hum Vaccin Immunother. 2014.
- van den Berg S, et al. Int J Med Microbiol. 2015.
- Bispo M, et al. JCI Insight. 2020.



CONTACT

Taher M. M. Alawneh
Department of Orthopedics, UMCG
Personalized Medicine Research
Institute, Groningen
MBM – Man, Biomaterials, Microbes
email: t.m.m.alawneh@umcg.nl



university of
groningen

umcg:



MolBac

